Niu Zhao-Shan, Niu Xiao-Jun, Wang Mei
Zhao-Shan Niu, Lab of Micromorphology, Medical College of Qingdao University, Qingdao 266071, Shandong Province, China.
World J Hepatol. 2015 Jan 27;7(1):7-27. doi: 10.4254/wjh.v7.i1.7.
Hepatocellular carcinoma (HCC) accounts for over 90% of all primary liver cancers. With an ever increasing incidence trend year by year, it has become the third most common cause of death from cancer worldwide. Hepatic resection is generally considered to be one of the most effective therapies for HCC patients, however, there is a high risk of recurrence in postoperative HCC. In clinical practice, there exists an urgent need for valid prognostic markers to identify patients with prognosis, hence the importance of studies on prognostic markers in improving the prediction of HCC prognosis. This review focuses on the most promising immunohistochemical prognostic markers in predicting the postoperative survival of HCC patients.
肝细胞癌(HCC)占所有原发性肝癌的90%以上。随着其发病率逐年呈上升趋势,它已成为全球癌症死亡的第三大常见原因。肝切除术通常被认为是治疗HCC患者最有效的方法之一,然而,HCC术后复发风险很高。在临床实践中,迫切需要有效的预后标志物来识别预后患者,因此研究预后标志物对改善HCC预后预测具有重要意义。本综述重点关注预测HCC患者术后生存最有前景的免疫组化预后标志物。